| Factors compared between biologics and biosimilars |
|---|
|
FDA: Food and Drug Administration
LNM and DM: Writing—original draft, Writing—review & editing. SRF: Conceptualization, Supervision, Writing—review & editing. All authors read and approved the submitted version.
Steven R. Feldman has received research, speaking and/or consulting support from a variety of companies including Galderma, GSK/Stiefel, Almirall, Leo Pharma, Boehringer Ingelheim, Mylan, Celgene, Pfizer, Valeant, Abbvie, Samsung, Janssen, Lilly, Menlo, Merck, Novartis, Regeneron, Sanofi, Novan, Qurient, National Biological Corporation, Caremark, Advance Medical, Sun Pharma, Suncare Research, Informa, UpToDate, and National Psoriasis Foundation. He is the founder and majority owner of http://www.drscore.com/ and founder and part-owner of Causa Research, a company dedicated to enhancing patients’ adherence to treatment. The other authors have no conflicts to disclose.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
Not applicable.
© The Author(s) 2025.
Open Exploration maintains a neutral stance on jurisdictional claims in published institutional affiliations and maps. All opinions expressed in this article are the personal views of the author(s) and do not represent the stance of the editorial team or the publisher.